Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-2575 Monotherapy in Relapsed or Refractory CLL/SLL
NCT05147467Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Dec 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisaftoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Ascentage Pharma. Primary endpoint: Objective Response Rate at 9 months. Started Dec 2021; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05147467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147467.